SUMMARY One hundred patients with radiolucent gall stones -1 5 cm in functioning gall bladders have received oral bile acid dissolution therapy since 1975. Complete data are available on 93 who have received at least six months' treatment. The complete dissolution rate in appropriately selected patients who complied with and tolerated an adequate course of treatment was 55%. By life table analysis the recurrence rates were 13% at one year, 21% at two years, 31% at three years, and 43% at four years. Thereafter the recurrence rate levelled out, being 49% at 11 years. Redissolution was achieved in all seven patients who had a second course of therapy, but was usually followed by rerecurrence. Patients whose gall stones recurred did not differ significantly from those who remained stone free with respect to age, sex, body weight, or time required for dissolution.
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Although the treatment of gall stones with a bile acid mixture had been reported as early as 1937,' it was not until the first descriptions of gall stone dissolution by pure chenodeoxycholic acid (CDCA) in 197223 that this mode of therapy entered clinical practice. Since then there have been numerous advances in the medical treatment of gall stones. The optimum patient selection criteria and drug dosage have been defined.4 A second agent, ursodeoxycholic acid (UDCA) which has a number of advantages over CDCA has been introduced. 5 Ultrasonography is now widely used in the diagnosis and monitoring of gall stone disease and provides information complementary to that obtained from oral cholecystography. 6 Recurrence of gall stones after successful dissolution is common and is a major disincentive to treatment.' The longterm outcome of successfully treated patients is ill defined, however, as is the best way to manage recurrences. The factors determining recurrence are also unknown. Over the past 11 Recurrence and re-recurrence ofgall stones after medical dissolution: a longterm follow up 657 ceptive use did not influence recurrence but the numbers involved were small.
DISSOLUTION OF RECURRENT STONES AND RE-RECURRENCE
Seven patients with recurrent stones opted for a second course of bile acid therapy. This led to complete redissolution in all seven. The patients were then followed up in standard fashion. One was lost to follow up. Re-recurrence was observed in four patients, in each case within 24 months of stopping treatment. Only two patients are known to be stone free, after 12 and 48 months of follow up. One patient with re-recurrence had a third course of bile acid therapy but when this had failed to produce dissolution of her gall stones within eight months she opted to have surgery.
Discussion
This study shows that, in appropriately selected patients, an adequate course of medical treatment produces complete dissolution of gall stones in up to 55% of cases and that approximately 50% of these patients can expect to remain stone free in the long term. Medical treatment of patients with recurrent gall stones is highly successful but further recurrence is likely after stopping treatment.
Using selection criteria similar to ours other workers have reported complete dissolution rates of 5-75%.4"' Low rates occurred when inadequate dosage of bile acids were used.9 High dissolution rates of 70-80% have been reported in studies with high exclusion rates. "' Previous reports of dissolution rates on an intention-to-treat basis are in accordance with our figure of approximately 45%."
Because it takes into account patients who have been lost to follow up and also the Recurrence of gall stones after successful dissolution is not unexpected as, after cessation of bile acid therapy, bile reverts to being supersaturated in the vast majority of patients.""'7 Only 50% of patients, however, get recurrence in the long term. This implies there are other factors besides supersaturation of bile which determine recurrence. Changes in gall bladder motor function,"9 nucleating factors,20 and crystallisation inhibitors2"22 are thought to be involved in the pathogenesis of gall stones. We suggest they are also important in determining whether gall stones recur and re-recur after successful dissolution. This hypothesis could be tested by doing the appropriate studies of bile and gall bladder function in patients whose gall stones dissolve and relating the findings to the subsequent outcome in terms of recurrence. Meanwhile, the most appropriate way to manage patients whose gall stones have been dissolved remains unknown. 
